米托蒽醌治疗晚期肾癌：欧洲癌症研究与治疗组织泌尿生殖系统癌症合作组针对既往未接受过治疗的患者开展的一项II期研究。
Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
作者信息
van Oosterom A T, Fosså S D, Pizzocaro G, Bergerat J P, Bono A V, De Pauw M, Sylvester R
出版信息
Eur J Cancer Clin Oncol. 1984 Oct;20(10):1239-41. doi: 10.1016/0277-5379(84)90253-0.
PMID:6541582
Abstract
Mitoxantrone at a dose of 15 mg/m2 i.v. q 3 weeks failed to produce responses in 29 adequately treated patients with measurable advanced renal cell carcinoma. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result, the application of mitoxantrone in this disease is not recommended.
摘要
对于29例经过充分治疗的可测量的晚期肾细胞癌患者，每3周静脉注射15 mg/m²的米托蒽醌未产生疗效。在这组身体状况良好的患者中观察到的副作用通常较轻。基于这一阴性结果，不建议在该疾病中应用米托蒽醌。
Zotero 插件